Overview

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia

Status:
Active, not recruiting

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborators:

argenx
argenx BVBA

Treatments:

Azacitidine
Venetoclax